Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.

Published

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: JAMA Psychiatry
Date: 2026-05-01
Source: Crossref
DOI: 10.1001/jamapsychiatry.2026.0132
PubMed: 41848690

Derived topics and classifications

psilocybin Depression Clinical Trial Treatment-Resistant Depression Safety Adverse Events Clinical Trial

Citation graph

35 referenced DOIs found in stored source metadata. 5 indexed papers cite this DOI.

Open citation network

10.1016/s0140-6736(24)00757-8 10.1001/jamapsychiatry.2022.3860 10.1186/s12888-019-2222-4 10.1016/s2215-0366(16)30065-7 10.1016/j.medj.2024.01.005 10.1001/jamapsychiatry.2020.3285 10.1016/j.eclinm.2022.101809 10.1001/jama.2023.14530 10.1056/nejmoa2206443 10.1056/nejmoa2032994 10.1136/bmj-2023-078084 10.1016/j.nsa.2022.100104

Indexed papers citing this DOI

Cardiovascular safety of psilocybin in psychiatric practice: a narrative review2026-08-01 PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW2026-06-24 Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial2026-05-27 Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression2026-05-01 Enlightenment in a Pill-Testing the Efficacy of Psilocybin2026-05-01

Related papers

The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidenceZenodo (CERN European Organization for Nuclear Research) · 2026-01-26 Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.Psychiatry research · 2025-02-01 The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023-01-01 Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.Med (New York, N.Y.) · 2024-03-08 EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEWInternational Journal of Innovative Technologies in Social Science · 2026-09-21 Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disordersnpj Mental Health Research · 2026-09-16 PSYCHEDELICS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER AND DEPRESSION: A REVIEW OF CLINICAL TRIALSInternational Journal of Innovative Technologies in Social Science · 2026-08-31 From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10